Definitive Healthcare Corp. (DH) stock
DHNasdaqServices-Prepackaged SoftwareFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3067% below fair value
$1.31+0.06 (+4.80%)
Close on Nov 13, 2026Market cap $139.84MP/E –Yield –
Earnings
Definitive Healthcare's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$54.70M
-8.8% on a year earlier
Adjusted Net Income Per Share, Q3 FY2026
$0.06
$0.07 a year earlier
Latest guidance
Raised
Aug 10, 2026 · 12 items
Quarterly results
Revenue and earnings per share from each of Definitive Healthcare's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $54.70M | -8.8% | -$0.04 | $0.06 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026after the close | $55.20M | -9.2% | -$0.05 | $0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $55.90M | -5.6% | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $61.50M | -1.3% | -$0.09 | $0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $60.00M | -4.3% | -$0.14 | $0.07 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $60.80M | – | -$0.07 | $0.07 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $59.20M | -7.1% | -$0.95 | $0.05 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $62.30M | -5.5% | -$0.51 | $0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $62.70M | -4.0% | -$1.12 | $0.10 | Release |
| Q1 FY2024ended Jun 30, 2024 | Aug 5, 2024after the close | $63.70M | +7.6% | -$1.81 | $0.09 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $65.90M | +8.7% | -$0.09 | $0.07 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $65.30M | +13.8% | -$1.50 | $0.09 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | $61.00M | +11.9% | -$0.08 | $0.08 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $59.20M | +18.2% | -$0.11 | $0.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $60.60M | +30.9% | $0.07 | $0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $57.40M | +33.2% | -$0.03 | $0.06 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $54.50M | – | -$0.05 | $0.06 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $50.10M | – | -$0.09 | $0.05 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $46.30M | – | -$0.10 | $0.04 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021after the close | $43.10M | – | -$0.09 | $0.01 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Definitive Healthcare's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $220.00M – $222.00M | $220.00M – $226.00M | Lowered | Aug 10, 2026 |
| Revenuenon-GAAP | FY2026 | $220.00M – $226.00M | – | New | Feb 26, 2026 |
| Adjusted Operating Incomenon-GAAP | FY2026 | $45.50M – $47.50M | $43.50M – $47.50M | Raised | Aug 10, 2026 |
| adjusted EBITDA Marginnon-GAAP | FY2026 | 26% – 27% | – | New | Aug 10, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $57.00M – $59.00M | $55.00M – $59.00M | Raised | Aug 10, 2026 |
| Adjusted Net Income Per Diluted Sharenon-GAAP | FY2026 | $0.18 – $0.20 | $0.16 – $0.19 | Raised | Aug 10, 2026 |
| adjusted EBITDA marginnon-GAAP | FY2026 | 25% – 26% | 24% – 26% | Raised | May 7, 2026 |
| Adjusted Net Incomenon-GAAP | FY2026 | $27.00M – $29.00M | $23.00M – $27.00M | Raised | Aug 10, 2026 |
Guidance vs results
The last range Definitive Healthcare gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Adjusted Net Income Per Diluted Share | $0.04 – $0.05 | $0.06 | Above range |
| Q3 FY2026 | Revenue | $54.00M – $55.00M | $54.70M | Within range |
| Q2 FY2026 | Adjusted Net Income Per Diluted Share | $0.03 – $0.04 | $0.05 | Above range |
| Q2 FY2026 | Revenue | $55.00M – $56.00M | $55.20M | Within range |
| Q1 FY2026 | Revenue | $54.00M – $56.00M | $55.90M | Within range |
| FY2025 | Adjusted Net Income Per Diluted Share | $0.23 – $0.24 | $0.25Σ4Q | Above range |
| FY2025 | Revenue | $239.00M – $240.00M | $241.50MΣ4Q | Above range |
| Q4 FY2025 | Adjusted Net Income Per Diluted Share | $0.05 – $0.06 | $0.06 | Within range |
| Q4 FY2025 | Revenue | $59.00M – $60.00M | $61.50M | Above range |
| Q3 FY2025 | Adjusted Net Income Per Diluted Share | $0.05 – $0.06 | $0.07 | Above range |
| Q3 FY2025 | Revenue | $59.00M – $60.00M | $60.00M | Within range |
| Q2 FY2025 | Adjusted Net Income Per Diluted Share | $0.04 – $0.05 | $0.07 | Above range |
| Q2 FY2025 | Revenue | $58.50M – $60.00M | $60.80M | Above range |
| Q1 FY2025 | Adjusted Net Income Per Diluted Share | $0.02 | $0.05 | Above range |
| Q1 FY2025 | Revenue | $55.50M – $57.00M | $59.20M | Above range |
| Q4 FY2024 | Adjusted Net Income Per Diluted Share | $0.07 | $0.08 | Above range |
| Q4 FY2024 | Revenue | $60.00M – $61.00M | $62.30M | Above range |
| Q3 FY2024 | Adjusted Net Income Per Diluted Share | $0.07 – $0.08 | $0.10 | Above range |
| Q3 FY2024 | Revenue | $61.00M – $62.50M | $62.70M | Above range |
| Q1 FY2024 | Adjusted Net Income Per Diluted Share | $0.07 – $0.08 | $0.09 | Above range |
| Q1 FY2024 | Revenue | $63.00M – $65.00M | $63.70M | Within range |
| Q4 FY2023 | Adjusted Net Income Per Diluted Share | $0.06 – $0.08 | $0.07 | Within range |
| Q4 FY2023 | Revenue | $65.50M – $66.50M | $65.90M | Within range |
| Q3 FY2023 | Adjusted Net Income Per Diluted Share | $0.05 – $0.07 | $0.09 | Above range |
| Q3 FY2023 | Revenue | $63.00M – $64.50M | $65.30M | Above range |
| Q2 FY2023 | Adjusted Net Income Per Diluted Share | $0.03 – $0.05 | $0.08 | Above range |
| Q2 FY2023 | Revenue | $60.50M – $61.50M | $61.00M | Within range |
| Q1 FY2023 | Adjusted Net Income Per Diluted Share | $0.03 – $0.05 | $0.06 | Above range |
| Q1 FY2023 | Revenue | $56.50M – $58.50M | $59.20M | Above range |
| Q4 FY2022 | Adjusted Net Income Per Diluted Share | $0.03 – $0.04 | $0.07 | Above range |
| Q4 FY2022 | Revenue | $58.00M – $59.00M | $60.60M | Above range |
| Q3 FY2022 | Adjusted Net Income Per Diluted Share | $0.03 – $0.05 | $0.06 | Above range |
| Q3 FY2022 | Revenue | $56.00M – $57.00M | $57.40M | Above range |
| Q2 FY2022 | Adjusted Net Income Per Diluted Share | $0.04 – $0.05 | $0.06 | Above range |
| Q2 FY2022 | Revenue | $53.00M – $54.00M | $54.50M | Above range |
| Q1 FY2022 | Adjusted Net Income Per Diluted Share | $0.02 – $0.04 | $0.05 | Above range |
| Q1 FY2022 | Revenue | $47.00M – $49.00M | $50.10M | Above range |
| Q4 FY2021 | Adjusted Net Income Per Diluted Share | $0.04 – $0.05 | $0.04 | Within range |
| Q4 FY2021 | Revenue | $44.00M – $45.00M | $46.30M | Above range |
Guidance history
Every forecast Definitive Healthcare put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 10, 2026 | Adjusted EBITDA | FY2026 | $57.00M – $59.00M | Raised |
| Aug 10, 2026 | Adjusted EBITDA | Q3 FY2026 | $13.50M – $14.50M | New |
| Aug 10, 2026 | Adjusted Net Income Per Diluted Share | FY2026 | $0.18 – $0.20 | Raised |
| Aug 10, 2026 | Adjusted Net Income Per Diluted Share | Q3 FY2026 | $0.04 – $0.05 | New |
| Aug 10, 2026 | Adjusted Operating Income | FY2026 | $45.50M – $47.50M | Raised |
| Aug 10, 2026 | Adjusted Operating Income | Q3 FY2026 | $10.50M – $11.50M | New |
| Aug 10, 2026 | adjusted EBITDA Margin | FY2026 | 26% – 27% | New |
| Aug 10, 2026 | adjusted EBITDA Margin | Q3 FY2026 | 25% – 27% | New |
| Aug 10, 2026 | Adjusted Net Income | FY2026 | $27.00M – $29.00M | Raised |
| Aug 10, 2026 | Adjusted Net Income | Q3 FY2026 | $5.50M – $6.50M | New |
| Aug 10, 2026 | Revenue | FY2026 | $220.00M – $222.00M | Lowered |
| Aug 10, 2026 | Revenue | Q3 FY2026 | $54.00M – $55.00M | New |
| May 7, 2026 | Adjusted EBITDA | FY2026 | $55.00M – $59.00M | Raised |
| May 7, 2026 | Adjusted EBITDA | Q2 FY2026 | $13.50M – $14.50M | New |
| May 7, 2026 | Adjusted Net Income Per Diluted Share | FY2026 | $0.16 – $0.19 | Raised |
| May 7, 2026 | Adjusted Net Income Per Diluted Share | Q2 FY2026 | $0.03 – $0.04 | New |
| May 7, 2026 | Adjusted Operating Income | Q2 FY2026 | $10.50M – $11.50M | New |
| May 7, 2026 | Adjusted Operating Income | FY2026 | $43.50M – $47.50M | Raised |
| May 7, 2026 | Adjusted Net Income | FY2026 | $23.00M – $27.00M | Raised |
| May 7, 2026 | adjusted EBITDA margin | FY2026 | 25% – 26% | Raised |
| May 7, 2026 | adjusted EBITDA margin | Q2 FY2026 | 24% – 26% | New |
| May 7, 2026 | Adjusted Net Income | Q2 FY2026 | $5.00M – $6.00M | New |
| May 7, 2026 | Revenue | FY2026 | $220.00M – $226.00M | New |
| May 7, 2026 | Revenue | Q2 FY2026 | $55.00M – $56.00M | New |
| Feb 26, 2026 | Adjusted EBITDA | FY2026 | $53.00M – $58.00M | New |
| Feb 26, 2026 | Adjusted EBITDA | Q1 FY2026 | $12.00M – $13.00M | New |
| Feb 26, 2026 | Adjusted Net Income Per Diluted Share | FY2026 | $0.14 – $0.17 | New |
| Feb 26, 2026 | Adjusted Net Income Per Diluted Share | Q1 FY2026 | $0.03 | New |
| Feb 26, 2026 | Adjusted Operating Income | FY2026 | $41.50M – $46.50M | New |
| Feb 26, 2026 | Adjusted Operating Income | Q1 FY2026 | $9.50M – $10.50M | New |
| Feb 26, 2026 | adjusted EBITDA margin | FY2026 | 24% – 26% | New |
| Feb 26, 2026 | Adjusted Net Income | FY2026 | $21.00M – $26.00M | New |
| Feb 26, 2026 | adjusted EBITDA margin | Q1 FY2026 | 22% – 23% | New |
| Feb 26, 2026 | Adjusted Net Income | Q1 FY2026 | $4.00M – $5.00M | New |
| Feb 26, 2026 | Revenue | FY2026 | $220.00M – $226.00M | New |
| Feb 26, 2026 | Revenue | Q1 FY2026 | $54.00M – $56.00M | New |
| Nov 6, 2025 | Adjusted EBITDA | FY2025 | $68.00M – $69.00M | New |
| Nov 6, 2025 | Adjusted EBITDA | Q4 FY2025 | $16.00M – $17.00M | New |
| Nov 6, 2025 | Adjusted Net Income Per Diluted Share | FY2025 | $0.23 – $0.24 | New |
| Nov 6, 2025 | Adjusted Net Income Per Diluted Share | Q4 FY2025 | $0.05 – $0.06 | New |
| Nov 6, 2025 | Adjusted Operating Income | FY2025 | $57.50M – $58.50M | New |
| Nov 6, 2025 | Adjusted Operating Income | Q4 FY2025 | $13.50M – $14.50M | New |
| Nov 6, 2025 | adjusted EBITDA margin | FY2025 | 28% – 29% | New |
| Nov 6, 2025 | adjusted EBITDA margin | Q4 FY2025 | 27% – 29% | New |
| Nov 6, 2025 | Adjusted Net Income | FY2025 | $34.00M – $35.00M | New |
| Nov 6, 2025 | Adjusted Net Income | Q4 FY2025 | $8.00M – $9.00M | New |
| Nov 6, 2025 | Revenue | FY2025 | $239.00M – $240.00M | New |
| Nov 6, 2025 | Revenue | Q4 FY2025 | $59.00M – $60.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | Q3 FY2025 | $15.50M – $16.50M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $64.00M – $67.00M | Raised |
| Aug 7, 2025 | Adjusted Net Income Per Diluted Share | Q3 FY2025 | $0.05 – $0.06 | New |
| Aug 7, 2025 | Adjusted Net Income Per Diluted Share | FY2025 | $0.22 – $0.23 | Raised |
| Aug 7, 2025 | Adjusted Operating Income | Q3 FY2025 | $12.50M – $13.50M | New |
| Aug 7, 2025 | Adjusted Operating Income | FY2025 | $52.00M – $55.00M | Raised |
| Aug 7, 2025 | adjusted EBITDA margin | Q3 FY2025 | 26% – 28% | New |
| Aug 7, 2025 | Adjusted Net Income | Q3 FY2025 | $7.50M – $8.50M | New |
| Aug 7, 2025 | adjusted EBITDA margin | FY2025 | 27% – 28% | Raised |
| Aug 7, 2025 | Adjusted Net Income | FY2025 | $32.50M – $34.50M | Raised |
| Aug 7, 2025 | Revenue | Q3 FY2025 | $59.00M – $60.00M | New |
| Aug 7, 2025 | Revenue | FY2025 | $237.00M – $240.00M | Raised |
| May 8, 2025 | Adjusted EBITDA | Q2 FY2025 | $15.00M – $16.00M | New |
| May 8, 2025 | Adjusted EBITDA | FY2025 | $61.00M – $65.00M | Reaffirmed |
| May 8, 2025 | Adjusted Net Income Per Diluted Share | Q2 FY2025 | $0.04 – $0.05 | New |
| May 8, 2025 | Adjusted Net Income Per Diluted Share | FY2025 | $0.20 – $0.23 | Raised |
| May 8, 2025 | Adjusted Operating Income | Q2 FY2025 | $12.00M – $13.00M | New |
| May 8, 2025 | Adjusted Operating Income | FY2025 | $49.00M – $53.00M | Reaffirmed |
| May 8, 2025 | adjusted EBITDA margin | Q2 FY2025 | 25% – 27% | New |
| May 8, 2025 | full-year adjusted EBITDA margin | FY2025 | 26% – 28% | New |
| May 8, 2025 | Adjusted Net Income | Q2 FY2025 | $6.50M – $7.50M | New |
| May 8, 2025 | Adjusted Net Income | FY2025 | $30.00M – $34.00M | Reaffirmed |
| May 8, 2025 | Revenue | Q2 FY2025 | $58.50M – $60.00M | New |
| May 8, 2025 | Revenue | FY2025 | $234.00M – $240.00M | Raised |
| Feb 27, 2025 | Adjusted EBITDA | Q1 FY2025 | $10.50M – $11.50M | New |
| Feb 27, 2025 | Adjusted EBITDA | FY2025 | $61.00M – $65.00M | New |
| Feb 27, 2025 | Adjusted Net Income Per Diluted Share | Q1 FY2025 | $0.02 | New |
| Feb 27, 2025 | Adjusted Net Income Per Diluted Share | FY2025 | $0.19 – $0.22 | New |
| Feb 27, 2025 | Adjusted Operating Income | Q1 FY2025 | $7.50M – $8.50M | New |
| Feb 27, 2025 | Adjusted Operating Income | FY2025 | $49.00M – $53.00M | New |
| Feb 27, 2025 | adjusted EBITDA margin | Q1 FY2025 | 19% – 20% | New |
| Feb 27, 2025 | Adjusted Net Income | Q1 FY2025 | $3.00M – $4.00M | New |
| Feb 27, 2025 | full-year adjusted EBITDA margin | FY2025 | 26% – 28% | New |
| Feb 27, 2025 | Adjusted Net Income | FY2025 | $30.00M – $34.00M | New |
| Feb 27, 2025 | Revenue | Q1 FY2025 | $55.50M – $57.00M | New |
| Feb 27, 2025 | Revenue | FY2025 | $230.00M – $240.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | Q4 FY2024 | $16.00M – $17.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2024 | $77.50M – $78.50M | Raised |
| Nov 7, 2024 | Adjusted Net Income Per Diluted Share | Q4 FY2024 | $0.07 | New |
| Nov 7, 2024 | Adjusted Net Income Per Diluted Share | FY2024 | $0.34 – $0.35 | Raised |
| Nov 7, 2024 | Adjusted Operating Income | Q4 FY2024 | $14.00M – $15.00M | New |
| Nov 7, 2024 | Adjusted Operating Income | FY2024 | $71.00M – $72.00M | Raised |
| Nov 7, 2024 | adjusted EBITDA margin | Q4 FY2024 | 26% – 28% | New |
| Nov 7, 2024 | Adjusted Net Income | Q4 FY2024 | $10.50M – $11.50M | New |
| Nov 7, 2024 | full-year adjusted EBITDA margin | FY2024 | 31% | Raised |
| Nov 7, 2024 | Adjusted Net Income | FY2024 | $53.00M – $54.00M | Raised |
| Nov 7, 2024 | Revenue | Q4 FY2024 | $60.00M – $61.00M | New |
| Nov 7, 2024 | Revenue | FY2024 | $250.00M – $251.00M | Raised |
| Aug 5, 2024 | Adjusted EBITDA | Q3 FY2024 | $17.50M – $19.00M | New |
| Aug 5, 2024 | Adjusted EBITDA | FY2024 | $74.00M – $77.00M | Lowered |
| Aug 5, 2024 | Adjusted Net Income Per Diluted Share | Q3 FY2024 | $0.07 – $0.08 | New |
| Aug 5, 2024 | Adjusted Net Income Per Diluted Share | FY2024 | $0.32 – $0.34 | Lowered |
| Aug 5, 2024 | Adjusted Operating Income | Q3 FY2024 | $16.00M – $17.50M | New |
| Aug 5, 2024 | Adjusted Operating Income | FY2024 | $67.00M – $71.00M | Lowered |
| Aug 5, 2024 | adjusted EBITDA margin | Q3 FY2024 | 28% – 31% | New |
| Aug 5, 2024 | Adjusted Net Income | Q3 FY2024 | $12.00M – $13.00M | New |
| Aug 5, 2024 | full-year adjusted EBITDA margin | FY2024 | 30% – 31% | New |
| Aug 5, 2024 | Adjusted Net Income | FY2024 | $50.00M – $53.00M | Lowered |
| Aug 5, 2024 | Revenue | Q3 FY2024 | $61.00M – $62.50M | New |
| Aug 5, 2024 | Revenue | FY2024 | $247.00M – $251.00M | New |
| Feb 28, 2024 | Adjusted EBITDA | Q1 FY2024 | $19.50M – $20.50M | New |
| Feb 28, 2024 | Adjusted EBITDA | FY2024 | $84.00M – $88.00M | New |
| Feb 28, 2024 | Adjusted Net Income Per Diluted Share | Q1 FY2024 | $0.07 – $0.08 | New |
| Feb 28, 2024 | Adjusted Net Income Per Diluted Share | FY2024 | $0.37 – $0.40 | New |
| Feb 28, 2024 | Adjusted Operating Income | Q1 FY2024 | $18.00M – $19.00M | New |
| Feb 28, 2024 | Adjusted Operating Income | FY2024 | $78.00M – $82.00M | New |
| Feb 28, 2024 | Adjusted Net Income | Q1 FY2024 | $12.00M – $13.00M | New |
| Feb 28, 2024 | Adjusted Net Income | FY2024 | $59.00M – $63.00M | New |
| Feb 28, 2024 | Revenue | Q1 FY2024 | $63.00M – $65.00M | New |
| Feb 28, 2024 | Revenue | FY2024 | $263.00M – $269.00M | New |
| Nov 2, 2023 | Adjusted EBITDA | Q4 FY2023 | $19.00M – $20.00M | New |
| Nov 2, 2023 | Adjusted Net Income Per Diluted Share | Q4 FY2023 | $0.06 – $0.08 | New |
| Nov 2, 2023 | Adjusted Operating Income | Q4 FY2023 | $17.50M – $18.50M | New |
| Nov 2, 2023 | Adjusted Net Income | Q4 FY2023 | $11.50M – $12.50M | New |
| Nov 2, 2023 | Revenue | Q4 FY2023 | $65.50M – $66.50M | New |
| Aug 14, 2023 | Adjusted EBITDA | Q3 FY2023 | $17.50M – $18.50M | New |
| Aug 14, 2023 | Adjusted EBITDA | FY2023 | $67.00M – $71.00M | Reaffirmed |
| Aug 14, 2023 | Adjusted Net Income Per Diluted Share | Q3 FY2023 | $0.05 – $0.07 | New |
| Aug 14, 2023 | Adjusted Net Income Per Diluted Share | FY2023 | $0.19 – $0.23 | Reaffirmed |
| Aug 14, 2023 | Adjusted Operating Income | Q3 FY2023 | $16.00M – $17.00M | New |
| Aug 14, 2023 | Adjusted Operating Income | FY2023 | $61.50M – $65.50M | Reaffirmed |
| Aug 14, 2023 | Adjusted Net Income | Q3 FY2023 | $9.50M – $10.50M | New |
| Aug 14, 2023 | Adjusted Net Income | FY2023 | $30.00M – $34.00M | Reaffirmed |
| Aug 14, 2023 | Revenue | Q3 FY2023 | $63.00M – $64.50M | New |
| Aug 14, 2023 | Revenue | FY2023 | $249.00M – $255.00M | Reaffirmed |
| Aug 1, 2023 | Adjusted EBITDA | FY2023 | $67.00M – $71.00M | Reaffirmed |
| Aug 1, 2023 | Revenue | FY2023 | $249.00M – $255.00M | Reaffirmed |
| May 4, 2023 | Adjusted EBITDA | Q2 FY2023 | $16.00M – $17.00M | New |
| May 4, 2023 | Adjusted EBITDA | FY2023 | $67.00M – $71.00M | Reaffirmed |
| May 4, 2023 | Adjusted Net Income Per Diluted Share | Q2 FY2023 | $0.03 – $0.05 | New |
| May 4, 2023 | Adjusted Net Income Per Diluted Share | FY2023 | $0.19 – $0.23 | Reaffirmed |
| May 4, 2023 | Adjusted Operating Income | Q2 FY2023 | $14.50M – $15.50M | New |
| May 4, 2023 | Adjusted Operating Income | FY2023 | $61.50M – $65.50M | Reaffirmed |
| May 4, 2023 | Adjusted Net Income | Q2 FY2023 | $7.00M – $8.00M | New |
| May 4, 2023 | Adjusted Net Income | FY2023 | $30.00M – $34.00M | Reaffirmed |
| May 4, 2023 | Revenue | Q2 FY2023 | $60.50M – $61.50M | New |
| May 4, 2023 | Revenue | FY2023 | $249.00M – $255.00M | New |
| Feb 23, 2023 | Adjusted EBITDA | Q1 FY2023 | $15.00M – $16.00M | New |
| Feb 23, 2023 | Adjusted EBITDA | FY2023 | $67.00M – $71.00M | New |
| Feb 23, 2023 | Adjusted Net Income Per Diluted Share | Q1 FY2023 | $0.03 – $0.05 | New |
| Feb 23, 2023 | Adjusted Net Income Per Diluted Share | FY2023 | $0.19 – $0.23 | New |
| Feb 23, 2023 | Adjusted Operating Income | Q1 FY2023 | $13.50M – $14.50M | New |
| Feb 23, 2023 | Adjusted Operating Income | FY2023 | $61.50M – $65.50M | New |
| Feb 23, 2023 | Adjusted Net Income | Q1 FY2023 | $6.50M – $7.50M | New |
| Feb 23, 2023 | Adjusted Net Income | FY2023 | $30.00M – $34.00M | New |
| Feb 23, 2023 | Revenue | Q1 FY2023 | $56.50M – $58.50M | New |
| Feb 23, 2023 | Revenue | FY2023 | $249.00M – $255.00M | New |
| Nov 3, 2022 | Adjusted EBITDA | Q4 FY2022 | $16.00M – $17.00M | New |
| Nov 3, 2022 | Adjusted EBITDA | FY2022 | $63.00M – $64.00M | Lowered |
| Nov 3, 2022 | Adjusted Net Income Per Diluted Share | Q4 FY2022 | $0.03 – $0.04 | New |
| Nov 3, 2022 | Adjusted Net Income Per Diluted Share | FY2022 | $0.19 – $0.20 | Narrowed |
| Nov 3, 2022 | Adjusted Operating Income | Q4 FY2022 | $15.00M – $16.00M | New |
| Nov 3, 2022 | Adjusted Operating Income | FY2022 | $59.00M – $60.00M | Narrowed |
| Nov 3, 2022 | Adjusted Net Income | Q4 FY2022 | $6.00M – $7.00M | New |
| Nov 3, 2022 | Adjusted Net Income | FY2022 | $30.00M – $31.00M | Narrowed |
| Nov 3, 2022 | Revenue | Q4 FY2022 | $58.00M – $59.00M | New |
| Nov 3, 2022 | Revenue | FY2022 | $220.00M – $221.00M | Lowered |
| Aug 4, 2022 | Adjusted EBITDA | Q3 FY2022 | $15.50M – $16.50M | New |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $63.00M – $66.00M | Narrowed |
| Aug 4, 2022 | Adjusted Net Income Per Diluted Share | Q3 FY2022 | $0.03 – $0.05 | New |
| Aug 4, 2022 | Adjusted Net Income Per Diluted Share | FY2022 | $0.18 – $0.21 | Lowered |
| Aug 4, 2022 | Adjusted Operating Income | Q3 FY2022 | $14.50M – $15.50M | New |
| Aug 4, 2022 | Adjusted Operating Income | FY2022 | $58.50M – $61.50M | Narrowed |
| Aug 4, 2022 | Adjusted Net Income | Q3 FY2022 | $6.50M – $7.50M | New |
| Aug 4, 2022 | Adjusted Net Income | FY2022 | $29.00M – $32.00M | Lowered |
| Aug 4, 2022 | Revenue | Q3 FY2022 | $56.00M – $57.00M | New |
| Aug 4, 2022 | Revenue | FY2022 | $220.50M – $224.50M | Reaffirmed |
| May 5, 2022 | Adjusted EBITDA | Q2 FY2022 | $14.00M – $15.00M | New |
| May 5, 2022 | Adjusted EBITDA | FY2022 | $61.00M – $67.00M | Reaffirmed |
| May 5, 2022 | Adjusted Net Income Per Diluted Share | Q2 FY2022 | $0.04 – $0.05 | New |
| May 5, 2022 | Adjusted Net Income Per Diluted Share | FY2022 | $0.22 – $0.26 | Reaffirmed |
| May 5, 2022 | Adjusted Operating Income | Q2 FY2022 | $13.00M – $14.00M | New |
| May 5, 2022 | Adjusted Operating Income | FY2022 | $57.00M – $63.00M | Reaffirmed |
| May 5, 2022 | Adjusted Net Income | Q2 FY2022 | $7.00M – $8.00M | New |
| May 5, 2022 | Adjusted Net Income | FY2022 | $35.00M – $41.00M | Reaffirmed |
| May 5, 2022 | Revenue | Q2 FY2022 | $53.00M – $54.00M | New |
| May 5, 2022 | Revenue | FY2022 | $220.50M – $224.50M | Raised |
| Feb 23, 2022 | Adjusted EBITDA | Q1 FY2022 | $11.00M – $13.00M | New |
| Feb 23, 2022 | Adjusted EBITDA | FY2022 | $61.00M – $67.00M | New |
| Feb 23, 2022 | Adjusted Net Income Per Diluted Share | Q1 FY2022 | $0.02 – $0.04 | New |
| Feb 23, 2022 | Adjusted Net Income Per Diluted Share | FY2022 | $0.22 – $0.26 | New |
| Feb 23, 2022 | Adjusted Operating Income | Q1 FY2022 | $10.00M – $12.00M | New |
| Feb 23, 2022 | Adjusted Operating Income | FY2022 | $57.00M – $63.00M | New |
| Feb 23, 2022 | Adjusted Net Income | Q1 FY2022 | $4.00M – $6.00M | New |
| Feb 23, 2022 | Adjusted Net Income | FY2022 | $35.00M – $41.00M | New |
| Feb 23, 2022 | Revenue | Q1 FY2022 | $47.00M – $49.00M | New |
| Feb 23, 2022 | Revenue | FY2022 | $218.00M – $222.00M | New |
| Nov 8, 2021 | Adjusted EBITDA | Q4 FY2021 | $12.50M – $13.50M | New |
| Nov 8, 2021 | Adjusted EBITDA | FY2021 | $55.00M – $56.00M | New |
| Nov 8, 2021 | Adjusted Net Income Per Diluted Share | Q4 FY2021 | $0.04 – $0.05 | New |
| Nov 8, 2021 | Adjusted Net Income Per Diluted Share | FY2021 | $0.08 – $0.09 | New |
| Nov 8, 2021 | Adjusted Operating Income | Q4 FY2021 | $11.50M – $12.50M | New |
| Nov 8, 2021 | Adjusted Operating Income | FY2021 | $52.00M – $53.00M | New |
| Nov 8, 2021 | Adjusted Net Income | Q4 FY2021 | $6.00M – $7.00M | New |
| Nov 8, 2021 | Adjusted Net Income | FY2021 | $13.00M – $14.00M | New |
| Nov 8, 2021 | Revenue | Q4 FY2021 | $44.00M – $45.00M | New |
| Nov 8, 2021 | Revenue | FY2021 | $164.00M – $165.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Definitive Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?